{
    "nct_id": "NCT05899816",
    "official_title": "A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)",
    "inclusion_criteria": "* Age ≥ 18 years to 54 years with a diagnosis of AD according to the American Academy of Dermatology (AAD) Consensus Criteria (2014) present for at least 12 months\n* History of inadequate response to topical corticosteroids (TCS) of medium, high, or higher potency (with or without topical calcineurin inhibitors)\n* Subjects with previous systemic treatment for AD are also considered as inadequate responders to topical treatments and are potentially eligible to be included in the study after appropriate washout.\n* Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 54 Years",
    "exclusion_criteria": "* Treatment with a biologic product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1\n* Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:\n\n  * Systemic corticosteroids\n  * Systemic immunosuppressants\n  * Phototherapy\n  * Janus kinase inhibitors\n* Treatment with any of the following medications or therapies within 1 week, prior to Day 1:\n\n  * TCS of any potency\n  * Topical calcineurin inhibitors (TCI)\n  * Topical Phosphodiesterase-4 inhibitors (PDE4)\n  * Other topical immunosuppressive agents\n  * Combination topical agents containing a corticosteroid or calcineurin inhibiting component, PDE4 inhibitors, or other topical immunosuppressive agents\n* Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 pre-randomization.\n* Treatment with any meningococcal vaccine within 1 year prior to screening, or treatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5 years prior to screening",
    "miscellaneous_criteria": ""
}